Table 4.
Summary risk estimates of the subgroup analyses.
| Subgroup | Design | Study (No.) | RR (95% CI) | p-value |
Heterogeneity
(I2, p-value) |
|---|---|---|---|---|---|
| lp(a) 50 mg/dL group | |||||
| Study types | Cohort studies Case-control studies |
4 3 |
1.70 (1.39, 2.07) 2.73 (1.41, 5.28) |
p < 0.001 p = 0.003 |
76.7%, p = 0.005 0.0%, p = 0.666 |
| Countries | America Europe other |
2 4 1 |
1.45 (1.22, 1.72) 1.95 (1.93, 1.96) 4.19 (0.88–19.89) |
p < 0.001 p < 0.001 – |
0.0%, p = 0.857 0.0%, p = 0.562 – |
| Level of adjustment | ≥7 <7 |
4 3 |
1.48 (1.25, 1.75) 1.95 (1.88, 2.02) |
p < 0.001 p < 0.001 |
0.0%, p = 0.521 2.2%, p = 0.360 |
| lp(a) 30 mg/dL group | |||||
| Study types | Cohort studies Case-control studies |
2 3 |
1.38 (1.19, 1.61) 1.27 (0.78, 2.06) |
p < 0.001 p = 0.339 |
0.0%, p = 0.882 57.2%, p = 0.097 |
| Country | America Europe |
3 2 |
1.19 (0.87, 1.63) 1.75 (1.03, 2.99) |
p = 0.282 p = 0.038 |
78.7%, p = 0.009 0.0%, p = 0.917 |
| Level of adjustment | ≥6 <6 |
3 2 |
1.39 (1.20, 1.62) 1.18 (0.64, 2.17) |
p < 0.001 p = 0.590 |
0.0%, p = 0.873 65.9%, p = 0.087 |